Theratechnologies
Market Cap
CA$308.6m
Last Updated
2019/12/12 23:48 UTC
Data Sources
Company Financials +
Executive Summary
Theratechnologies Inc., a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients.
Rewards
Risk Analysis
Snowflake Analysis
Exceptional growth potential with mediocre balance sheet.
Share Price & News
How has Theratechnologies's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TH's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
6.9%
TH
44.2%
CA Biotechs
0.4%
CA Market
1 Year Return
-52.3%
TH
50.7%
CA Biotechs
10.6%
CA Market
Return vs Industry: TH underperformed the Canadian Biotechs industry which returned 50.7% over the past year.
Return vs Market: TH underperformed the Canadian Market which returned 10.6% over the past year.
Shareholder returns
| TH | Industry | Market | |
|---|---|---|---|
| 7 Day | 6.9% | 44.2% | 0.4% |
| 30 Day | -20.9% | 66.0% | 0.01% |
| 90 Day | -29.5% | 44.5% | 0.7% |
| 1 Year | -52.3%-52.3% | 50.7%50.7% | 14.3%10.6% |
| 3 Year | 44.2%44.2% | 55.3%55.3% | 15.9%5.4% |
| 5 Year | 878.0%878.0% | 108.6%108.6% | 35.2%15.2% |
Price Volatility Vs. Market
How volatile is Theratechnologies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
The Theratechnologies (TSE:TH) Share Price Is Up 821% And Shareholders Are Delighted1 month ago | Simply Wall St
Is Theratechnologies (TSE:TH) A Risky Investment?2 months ago | Simply Wall St
Could Theratechnologies Inc.'s (TSE:TH) Investor Composition Influence The Stock Price?Valuation
Is Theratechnologies undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: TH (CA$4.01) is trading below our estimate of fair value (CA$16.79)
Significantly Below Fair Value: TH is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: TH is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: TH is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TH is overvalued based on its PB Ratio (7.8x) compared to the CA Biotechs industry average (3.2x).
Next Steps
Future Growth
How is Theratechnologies forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
55.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.4%).
Earnings vs Market: TH is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: TH's is expected to become profitable in the next 3 years.
Revenue vs Market: TH's revenue (25.2% per year) is forecast to grow faster than the Canadian market (4.9% per year).
High Growth Revenue: TH's revenue (25.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TH's Return on Equity is forecast to be high in 3 years time (27.9%)
Next Steps
Past Performance
How has Theratechnologies performed over the past 5 years?
-11.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TH is currently unprofitable.
Growing Profit Margin: TH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TH is unprofitable, and losses have increased over the past 5 years at a rate of -11.8% per year.
Accelerating Growth: Unable to compare TH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (103.3%).
Return on Equity
High ROE: TH has a negative Return on Equity (-22.8%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Theratechnologies's financial position?
Financial Position Analysis
Short Term Liabilities: TH's short term assets ($68.8M) exceed its short term liabilities ($27.4M).
Long Term Liabilities: TH's short term assets ($68.8M) exceed its long term liabilities ($50.6M).
Debt to Equity History and Analysis
Debt Level: TH's debt to equity ratio (167.7%) is considered high.
Reducing Debt: Insufficient data to determine if TH's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Inventory Level: TH has a low level of unsold assets or inventory.
Debt Coverage by Assets: TH's debt is covered by short term assets (assets are 1.4x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TH has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if TH has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Theratechnologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate TH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate TH's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TH's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
What is the CEO of Theratechnologies's salary, the management and board of directors tenure and is there insider trading?
3.4yrs
Average management tenure
CEO
Luc Tanguay (61yo)
7.2yrs
Tenure
US$1,169,180
Compensation
Mr. Luc Tanguay, M.Sc., C.F.A. has been the Chief Executive Officer and President of Theratechnologies Inc. since October 11, 2012. Mr. Tanguay has been active in the biotechnology industry for over 20 yea ...
CEO Compensation Analysis
Compensation vs Market: Luc's total compensation ($USD886.76K) is about average for companies of similar size in the Canadian market ($USD682.76K).
Compensation vs Earnings: Luc's compensation has been consistent with company performance over the past year.
Management Age and Tenure
3.4yrs
Average Tenure
52.5yo
Average Age
Experienced Management: TH's management team is considered experienced (3.4 years average tenure).
Board Age and Tenure
13.8yrs
Average Tenure
66yo
Average Age
Experienced Board: TH's board of directors are seasoned and experienced ( 13.8 years average tenure).
Insider Trading
Insider Buying: TH insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 3,190 |
| Max Price | US$4.74 |
| Entity | Individual |
| Role | Chief Financial Officer Senior VP & CFO |
| Shares | 1,000 |
| Max Price | US$4.85 |
| Entity | Individual |
| Role | Chief Financial Officer Senior VP & CFO |
| Shares | 3,000 |
| Max Price | US$6.66 |
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Luc Tanguay (61yo)
President
- Tenure: 7.2yrs
- Compensation: US$1.17m
Jocelyn Lafond (51yo)
VP of Legal Affairs & Corporate Secretary
- Tenure: 0yrs
- Compensation: US$444.16k
Christian Marsolais (56yo)
Senior VP & Chief Medical Officer
- Tenure: 3.4yrs
- Compensation: US$582.29k
Philippe Dubuc (52yo)
Senior VP & CFO
- Tenure: 3.8yrs
- Compensation: US$596.33k
Denis Boucher (53yo)
Vice President of Communications & Corporate Affairs
- Tenure: 1.9yrs
- Compensation: US$457.30k
Jovan Antunovic (49yo)
Senior VP & Chief Commercial Officer
- Tenure: 1yrs
Board Members
Roger Guillemin
Member of the Scientific Advisory Board
- Tenure: 0yrs
Luc Tanguay (61yo)
President
- Tenure: 7.2yrs
- Compensation: US$1.17m
Gary Littlejohn (64yo)
Independent Director
- Tenure: 1.2yrs
- Compensation: US$8.00k
George Merriam
Member of the Scientific Advisory Board
- Tenure: 0yrs
David Clemmons
Member of the Scientific Advisory Board
- Tenure: 0yrs
Paul Pommier (77yo)
Independent Director
- Tenure: 22.9yrs
- Compensation: US$109.67k
Gérald Lacoste (75yo)
Independent Director
- Tenure: 13.8yrs
- Compensation: US$107.50k
Graham Svoronos (66yo)
Chair of the Board
- Tenure: 6.6yrs
- Compensation: US$208.00k
Steven Grinspoon
Member of the Scientific Advisory Board
- Tenure: 0yrs
Peter Reiss
Member of the Scientific Advisory Board
- Tenure: 0yrs
Company Information
Theratechnologies Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Theratechnologies Inc.
- Ticker: TH
- Exchange: TSX
- Founded: 1993
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$308.583m
- Shares outstanding: 76.95m
- Website: https://www.theratech.com
Number of Employees
Location
- Theratechnologies Inc.
- 2015 Peel Street
- 5th Floor
- Montreal
- Quebec
- H3A 1T8
- Canada
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| TH | TSX (The Toronto Stock Exchange) | Yes | Common Shares | CA | CAD | Dec 1993 |
| TQ8 | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Dec 1993 |
| THTX | NasdaqCM (Nasdaq Capital Market) | Yes | Common Shares | US | USD | Dec 1993 |
Biography
Theratechnologies Inc., a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of e ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/12/12 23:48 |
| End of Day Share Price | 2019/12/12 00:00 |
| Earnings | 2019/08/31 |
| Annual Earnings | 2018/11/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.